Overturning a negative HTA recommendation
The challenge
The client faced a significant obstacle when Canada’s Drug Agency (CDA, formerly CADTH) issued a negative reimbursement recommendation for their new drug submission. They were seeking opportunities for reconsideration, ultimately aiming to secure a positive final recommendation.
The approach
Our primary objective was to file a compelling request for reconsideration. We focused on understanding and addressing the key drivers in the reconsideration process, as well as the factors assessed by the CDA expert committee.
The outcome
Our collaborative efforts ultimately led to a positive reimbursement recommendation with conditions from CDA. With this positive Health Technology Assessment (HTA) decision, the client was able to advance to the next phase of the process, negotiation with the pan-Canadian Pharmaceutical Alliance (pCPA) for formulary listing.
From April 2021 to May 2024, only 7 of the 44 files that initially received negative recommendations from CDA were overturned to a final positive recommendation.
Cencora.com is providing automated translations to assist in reading the website in languages other than English. For these translations, reasonable efforts have been made to provide an accurate translation, however, no automated translation is perfect nor is it intended to replace human translators. These translations are provided as a service to users of Cencora.com and are provided "as is." No warranty of any kind, either expressed or implied, is made as to the accuracy, reliability, or correctness of any of these translations made from English into any other language. Some content (such as images, videos, Flash, etc.) may not be accurately translated due to the limitations of the translation software.
Any discrepancies or differences created in translating this content from English into another language are not binding and have no legal effect for compliance, enforcement, or any other purpose. If any errors are identified, please contact us. If any questions arise related to the accuracy of the information contained in these translations, please refer to the English version of the page.